A host of anti-inflammatory medicines are effective in treatment-resistant depression, particularly celecoxib.

Dubbed “California Rocket Fuel” by Stephen Stahl, the combination of venlafaxine and mirtazapine seemed to hit all the right receptors. The hype may have gotten a little ahead of the evidence on this one, however, as three new studies reveal.

Folic acid and l-methylfolate are two versions of the same vitamin. Both are popular for antidepressant augmentation, but one is a expensive prescription. We compared them side-by-side and found that one has a slight advantage.

With Vrylar’s new approval, there are now four atypicals antipsychotics with an indication in bipolar depression. Only two of these, however, are known to work in mania as well as depression. None of the atypicals stands out as the perfect choice for bipolar depression, but there are pros and cons to each that make them fitter better with certain patients.

On March 5, 2019, the FDA approved esketamine (Spravato) nasal spray as add-on therapy to traditional antidepressant medications for treatment-resistant depression (TRD). In this article, I will describe the events that led to esketamine’s development, review the data submitted to the FDA, and discuss what the future might hold for esketamine.

Certain psychiatric treatments require both the healthcare provider and patient to enroll in a Risk Evaluation and Mitigation Strategy (REMS) program before they are administered. Here are links to enroll.

Every week of depression takes a toll on infant development, so this rapid-acting treatment fills a unique need. Here we review the clinical data and the pragmatics of getting patients connected with the therapy.

Lithium is underutilized in geriatric depression, but this study suggests it may have unique benefits there.